ArticleScientific reports2022
High serum concentrations of growth differentiation factor-15 and their association with Crohn's disease and a low skeletal muscle index.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Multi-Omics and Machine Learning-Based Characterization of the Lactylation Microenvironment and Biomarker Identification in Crohn's Disease Intestinal Fibrosis.International journal of molecular sciences · 2026Article
- Association between iron status and inflammation markers with GDF15 and BMP6 in inflammatory bowel disease: a single center cross-sectional study.BMC gastroenterology · 2026Article
- Growth differentiation factor 15 - a new molecular target in inflammatory bowel disease: Progress and challenges.World journal of gastroenterology · 2026Article
- Pleiotropic effects of GDF-15 to regulate nutritional status: perspectives from body composition to nutrition-related disorders.British journal of biomedical science · 2026Review
- Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease.World journal of gastroenterology · 2025Article
- The importance of growth differentiation factor 15 and interleukin 6 serum levels in inflammatory bowel diseases.Journal of physiology and biochemistry · 2025Article
- Circulating Muscle Markers for Sarcopenia in Peritoneal Dialysis.International journal of nephrology · 2025Review
- Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.World journal of gastroenterology · 2024Article
- Different roles of circulating and intramuscular GDF15 as markers of skeletal muscle health.Frontiers in endocrinology · 2024Article
- Role of growth differentiation factor 15 in cancer cachexia (Review).Oncology letters · 2023Review
- Scoping review on health-related physical fitness in patients with inflammatory bowel disease: Assessment, interventions, and future directions.World journal of gastroenterology · 2023Article
- Associations of Serum CXCL12α and CK Levels with Skeletal Muscle Mass in Older Adults.Journal of clinical medicine · 2023Article
- Review
- The Cytokine Growth Differentiation Factor-15 and Skeletal Muscle Health: Portrait of an Emerging Widely Applicable Disease Biomarker.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia comprises a low skeletal muscle index (SMI) and low muscle strength (MS) or low physical function. Many sarcopenia biomarkers have been reported. With Crohn's disease (CD), a low SMI is predictive of intestinal complications. Therefore, many CD studies have reported that sarcopenia is defined by SMI alone. This study investigated the sarcopenia frequency by assessing the SMI and MS of Japanese patients with CD and biomarkers predicting a low SMI. We evaluated the SMI using a bioelectrical impedance analysis, handgrip strength, and C-reactive protein, albumin, interleukin-6, tumor necrosis factor-α, growth differentiation factor (GDF)-8, and GDF-15 levels as biomarker candidates for 78 CD patients at our hospital. Sarcopenia and a low SMI were observed in 7.7% and 42.3% of the patients, respectively. There was a significant difference in the GDF-15 levels of the low SMI group and normal group according to the multivariate analysis (P = 0.028; odds ratio [OR], 1.001; 95% confidence interval [CI] 1.000-1.002). When evaluated by sex, males exhibited a negative correlation between the GDF-15 level and SMI (Pearson's r = - 0.414; P = 0.0031), and the multivariate analysis indicated a significant difference in the GDF-15 levels (P = 0.011; OR, 1.001; 95% CI 1.000-1.002). GDF-15 levels may indicate a low SMI with CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.